Thalidomide Combined with Transcatheter Arterial Chemoembolization (TACE) for Intermediate or Advanced Hepatocellular Carcinoma: a Systematic Review and GRADE Approach |
| |
| Authors: | Wenjie Yang1Dandan Wang1Litao Huang1Yue Chen2Shu Wen3Qi Hong1Deying Kang1 |
| |
| Affiliation: | 1Department of Evidence-Based Medicine and Clinical Epidemiology, West China Hospital, Sichuan University, Chengdu, China.2Department of Thoracic Oncology, Cancer Center, State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy, West China Hospital, Medical School, Sichuan University, Chengdu, China.3West China School of Medicine and West China Hospital, Sichuan University, Chengdu, China. |
| |
| Abstract: | Objective:According to current guidelines, there is no clear second-line treatment for advanced liver cancer.In practice, clinicians have attempted to use thalidomide(TLD) combined with transcatheter arterial chemoembolization(TACE) for treating liver cancer. This study aims to assess the clinical efficacy and safety of TLD combined with TACEin patients with intermediate or advanced hepatocellular carcinoma. Methods: Medline, Embase, the Cochrane CentralRegister of Controlled Trials (CENTRAL), database of ClinicalTrials.gov, CBM, CNKI, VIP and Wanfang databasewere searched for eligible studies. Criteria for inclusion in our meta-analysis included a study that patients diagnosedwith intermediate or advanced HCC, the use of TACE plus TLD or its derivatives, and the availability of outcomedata for survival. A meta-analysis was conducted to summarize the evidences of randomized controlled trials (RCTs).And finally, the GRADE approach was used to assess the quality of these evidences. Results: Twelve RCTs involving894 Hepatocellular Carcinoma (HCC) patients were included. The meta-analysis results showed that TACE plus TLD wassignificantly superior than TACE alone in terms of 12-month survival rate (OR=2.55, 95% CI:1.78-3.64, P<0.01), 24-monthsurvival rate (OR=2.95, 95% CI:1.96-4.44, P<0.01), 36-month survival rate (OR=2.95, 95% CI:1.41-6.19, P<0.004),progression-free survival (PFS) (MD=2.23, 95% CI:1.19-3.28 , P<0.001), objective response rate (OR=1.84, 95%CI:1.34-2.52, P<0.0001), and disease control rate (OR=2.68, 95% CI:1.80-3.99). Subgroup analysis demonstratedno differences across related outcomes. Sensitivity analyses showed no important differences in the estimates ofeffects. Quality of evidence for all outcomes was rated moderate to very low after applying GRADE approach.Conclusions: Current evidence seemed to support the suggestion that TACE plus TLD as the second line treatment forpatients with intermediate or advanced HCC. However, this finding is not definitive due to the poor quality of includedstudies, more carefully designed and conducted RCTs are warranted to confirm above conclusions. |
| |
| Keywords: | Carcinoma Hepatocellular Chemoembolization Thalidomide Systematic review |
|
| 点击此处可从《Asian Pacific journal of cancer prevention》浏览原始摘要信息 |
|
点击此处可从《Asian Pacific journal of cancer prevention》下载免费的PDF全文 |
|
